A new clinical trial offers a promising avenue for treating major depressive disorder, exploring the potential of dimethyltryptamine (DMT), a psychedelic compound found in the Amazonian brew ayahuasca. Published this month in in Nature, the phase II trial suggests that a single dose of DMT, combined with supportive psychotherapy, can lead to significant and lasting reductions in depressive symptoms.
The study, led by Dr. David Erritzoe, a psychiatrist and neuroscientist at Imperial College London, involved 34 participants experiencing moderate to severe depression. Seventeen received an injection of a synthetic DMT compound developed by Small Pharma (now Cybin UK), while the other 17 received a placebo. All participants also received psychotherapeutic support. Two weeks after the injection, those who received DMT demonstrated a greater reduction in depressive symptoms compared to the placebo group.
This research builds on growing interest in psychedelic-assisted therapies as a novel approach to mental health. However, this trial distinguishes itself from traditional ayahuasca ceremonies. Ayahuasca typically involves a prolonged psychedelic experience induced by a tea containing DMT and other compounds, often accompanied by nausea and vomiting. The formulation used in this trial delivered a short, intense 30-minute experience via injection, potentially offering practical advantages in terms of cost and safety, according to researchers.
“The DMT psychedelic experience is far shorter – lasting minutes rather than hours – it could offer similar benefits at reduced cost and with a similar safety profile,” explained Dr. Erritzoe in a news release.
The Role of Therapy and the Nuances of Psychedelic Experience
Researchers emphasize that the therapeutic support surrounding the DMT experience is crucial. Tommaso Barba, a PhD candidate at Imperial College London and one of the study’s authors, highlighted the importance of preparing patients for the experience and helping them integrate it into their lives afterward. He cautioned that the trial was small and preliminary, stating, “There’s still more to do, but it’s promising.”
Interestingly, the traditional ayahuasca experience often includes vomiting, which some researchers believe can have a cathartic effect, allowing patients to process and release trauma. Dr. Daniel Perkins, a senior research fellow at the University of Melbourne’s psychedelics research and therapeutics unit, explained that while vomiting can be emotionally releasing for some, the study couldn’t definitively link it to improved outcomes.
The study’s approach, utilizing a short-acting injectable DMT formulation with focused psychotherapy, differs from traditional ayahuasca rituals, which incorporate chanting and other ceremonial elements. This highlights a broader trend in psychedelic-assisted therapy: a structured, facilitated experience designed to maximize therapeutic benefit.
Context within the Expanding Field of Psychedelic Therapies
The potential of DMT as a treatment for depression arrives alongside other advancements in the field of psychedelic-assisted therapies. In , the US Food and Drug Administration (FDA) approved Spravato, a ketamine-based nasal spray, for treatment-resistant depression – the first psychedelic-adjacent treatment to receive FDA approval. Clinical trials are also underway for psilocybin (the active component in “magic mushrooms”) and MDMA.
However, the FDA recently declined to approve MDMA-assisted therapy for post-traumatic stress disorder (PTSD) due to concerns regarding ethics and data reliability. Some researchers suggest that substances like psilocybin and DMT may be more suitable for therapeutic use, as there is some evidence suggesting they can offer benefits even outside of a clinical setting. In contrast, there is less evidence supporting inherent mental health benefits from recreational MDMA use. MDMA can induce a desire for physical touch, potentially creating uncomfortable situations with therapists – an effect not observed with DMT or psilocybin.
Challenges and Future Directions
Despite the promising results, several hurdles remain before DMT-assisted therapy becomes widely available. Barba noted that the FDA regulates drugs, not therapies and pharmaceutical companies may prioritize minimizing the therapeutic components of treatments to streamline development and approval. This could lead to a less comprehensive therapeutic experience for patients.
The current DMT therapy requires administration in a clinical setting via injection, alongside a therapist. This may be less appealing to some patients than a simple oral medication. Not everyone is comfortable with the prospect of an intense psychedelic experience.
Importantly, Barba emphasized that DMT is not a “quick fix” for depression. Rather, it can act as a catalyst, helping individuals gain insight into necessary changes in their mindset or lifestyle. He explained that lasting improvement often requires ongoing work with a therapist and a willingness to make difficult decisions. For example, if DMT helps a patient recognize that their job is contributing to their depression, they would likely need to consider changing careers to experience genuine relief.
The ongoing research into DMT and other psychedelics represents a significant shift in the approach to mental health treatment, offering hope for individuals who have not responded to traditional therapies. However, careful consideration of the therapeutic context, potential risks, and individual patient needs will be essential as these treatments continue to evolve.
